Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
408.6 DKK | -0.90% | -3.65% | +10.11% |
May. 10 | NOVONESIS : Key segments outperform in average Q1 24 showing | |
May. 03 | Transcript : Novozymes A/S, Q1 2024 Sales/ Trading Statement Call, May 03, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 87% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an expected P/E ratio at 48.6 and 33.85 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.11% | 27.6B | B+ | ||
-11.53% | 3.9B | - | C+ | |
+12.25% | 1.83B | C+ | ||
-4.30% | 683M | - | ||
-21.50% | 421M | - | - | |
-81.65% | 216M | - | - | |
-18.97% | 104M | - | - | |
-6.88% | 58.11M | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NSIS B Stock
- Ratings Novonesis A/S